120
Participants
Start Date
February 8, 2023
Primary Completion Date
February 1, 2026
Study Completion Date
February 1, 2027
Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
MRI
"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI
Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
Toxicity scoring
During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
RECRUITING
University Hospitals Ghent, Ghent
RECRUITING
UZ Leuven, Leuven
RECRUITING
Gasthuis Zusters Antwerpen, Wilrijk
University Hospital, Ghent
OTHER
Gasthuis Zusters Antwerpen
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER